australian financial review

HeartWare has the beating of its competitors
Date 23/3/2007
Author Henry Byrne
Source The Australian Financial Review -- Page: 62
The heart pump market is estimated to be worth about $US150m per annum. Australian-listed HeartWare's HVAD pump is not expected to be approved by the US Food & Drug Administration before mid-2010. HeartWare CEO Douglas Godshall says the market will be about triple its current size by then. Godshall believes that this expected growth is likely to attract the world's major medical device manufacturers to the heart pump sector. However, Godshall also believes that HeartWare - with a current market value of just $A135m - would be quite capable of taking its product to market by itself. He adds that HeartWare's product has many advantages over those of its rivals.